Mirati Therapeutics, Inc. (MRTX) Social Stream

Featured Post From StockTwits About MRTX

$KDMN, pegged at $500m annual peak sales and significant improvement in quality of life for chronic GVHD patients (meaning payers will provide coverage).

"Patients receiving [belumosudil] reported significant improvements in chronic GVHD symptoms, showing that not only did treatment result in organ responses, but it also made people feel better. This is so important for a chronic disease with a high symptom burden," Stephanie Lee, MD, MPH, professor at the Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, and research director of the Long-Term Follow-Up Program at Fred Hutchinson, noted in the release.

https://www.targetedonc.com/view/fda-approves-belumosudil-for-chronic-graft-versus-host-disease

$MRTX $GTHX $KPTI

What Else are MRTX Traders Talking About?

Other tickers frequently mentioned alongside MRTX are KDMN, GTHX and KPTI.